EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI

Ole Fröbert, Gregg W Stone, Alf Inge Larsen, Zhipeng Zhou, Lak N Kotinkaduwa, Thomas Engstrøm, Lars Kjøller-Hansen, Michael Maeng, Mitsuaki Matsumura, Ori Ben-Yehuda, Hans Erik Bøtker, Jonas Persson und 11 weitere

JACC: Cardiovascular Interventions · 2025

DOI: 10.1016/j.jcin.2025.01.440 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Ole Fröbert und 22 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Department of Cardiology, Örebro University, Örebro, Sweden; Department of Clinical Medicine, Faculty of Health, Aarhus University…. Hauptthemen laut MEDLINE: C-Reactive Protein, Coronary Artery Disease, Coronary Vessels, Inflammation Mediators. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Abbott Cardiovascular.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inflammation is a driver of atherosclerosis and susceptibility to cardiovascular events. OBJECTIVES: The authors sought to evaluate whether high-sensitivity C-reactive protein (hsCRP) levels are associated with the prevalence of high-risk coronary plaques in patients with non-ST-segment elevation myocardial infarction (NSTEMI). METHODS: PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II was a multicenter, prospective study enrolling patients with recent myocardial infarction. Following treatment of all flow-limiting lesions, 3-vessel imaging with near-infrared spectroscopy and intravascular ultrasound was used to characterize untreated nonculprit lesions. We investigated the association between baseline hsCRP and plaque morphology (lipid content, plaque burden, lumen area) in 501 NSTEMI patients. hsCRP levels were categorized as low ( 3 mg/L). RESULTS: The percentages of patients with at least 1 highly lipidic plaque (maximum lipid core burden index for any 4-mm pullback length ≥324.7) increased from 39.4% to 57.2% to 59.3% in the low, intermediate, and high hsCRP groups, respectively (P = 0.01). The proportion of patients with at least 1 highly lipidic plaque with ≥70% burden increased with hsCRP levels from 22.7% to 27.2% to 36.7%, respectively (P = 0.01). Multivariable analyses showed that increasing hsCRP was associated with higher total coronary artery lipid core burden index and plaque volume. Higher hsCRP increased the odds of having any highly lipidic plaque and those with ≥70% plaque burden. CONCLUSIONS: Among patients with recent NSTEMI, a high baseline hsCRP level was associated with the presence of pan-coronary atherosclerosis and focal high-risk plaques. (PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial; NCT02171065).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinCoronary Artery DiseaseCoronary VesselsInflammation MediatorsNon-ST Elevated Myocardial InfarctionPlaque, AtheroscleroticAgedFemaleHumansMaleMiddle AgedBiomarkersLipidsPercutaneous Coronary InterventionPredictive Value of TestsPrevalenceProspective StudiesRisk AssessmentRisk FactorsRupture, SpontaneousSpectroscopy, Near-InfraredTreatment OutcomeUltrasonography, InterventionalUp-Regulation

Stichwörter der Autor:innen

atherosclerosiscardiovascular event(s)coronary plaquesinflammationintravascular ultrasoundmyocardial infarctionnear-infrared spectroscopynon–ST-segment elevation myocardial infarction

Substanzen

BiomarkersC-Reactive ProteinInflammation MediatorsLipids

Autor:innen und Institutionen

  • Faculty of Health, Department of Cardiology, Örebro University, Örebro, Sweden; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark. Electronic address: ole.frobert@regionorebrolan.se.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Cardiology, Stavanger University Hospital, Stavanger, Norway and Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • University of Copenhagen, Copenhagen, Denmark.
  • Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.

Förderung

  • Abbott Cardiovascular

Zitieren

APA

Fröbert, O., Stone, G. W., Larsen, A. I., Zhou, Z., Kotinkaduwa, L. N., Engstrøm, T., Kjøller-Hansen, L., Maeng, M., Matsumura, M., Ben-Yehuda, O., Bøtker, H. E., Persson, J., Wiseth, R., Jensen, L. O., Nordrehaug, J. E., Trovik, T., Jensen, U., Bleie, Ø., James, S. K., …, & Maehara, A. (2025). Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.01.440

Vancouver

Fröbert O, Stone GW, Larsen AI, Zhou Z, Kotinkaduwa LN, Engstrøm T, et al. Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.01.440

BibTeX
@article{Frbert2025,
  author = {Fröbert, Ole and Stone, Gregg W and Larsen, Alf Inge and Zhou, Zhipeng and Kotinkaduwa, Lak N and Engstrøm, Thomas and Kjøller-Hansen, Lars and Maeng, Michael and Matsumura, Mitsuaki and Ben-Yehuda, Ori and Bøtker, Hans Erik and Persson, Jonas and Wiseth, Rune and Jensen, Lisette O and Nordrehaug, Jan E and Trovik, Thor and Jensen, Ulf and Bleie, Øyvind and James, Stefan K and Ali, Ziad A and Omerovic, Elmir and Erlinge, David and Maehara, Akiko},
  title = {Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1016/j.jcin.2025.01.440}
}
Kostenlos starten →